This was largely in response to requests from RCPAQAP participants to assist with the validation of their body fluid testing, given most in-vitro diagnostic device (IVDD) providers have no validation claims for these matrices.
Methods
The material is liquid with diluted human plasma as a base and supplemented to mimic a range of body fluids. The samples included in the pilot program had analyte levels consistent with a malignant ascites, a non-infectious pleural effusion and a parapneumonic effusion. Participants were asked to report values for the following chemistry analytes: albumin, amylase, cholesterol, creatinine, glucose, lactate, lactate dehydrogenase, lipase*, osmolality*, pH*, protein, sodium*, and triglycerides. They were also asked to report results for the following tumour markers: AFP*, CA 125*, CA 15-3*, CA 19-9, CEA, and hCG*. Results from 70 participating laboratories were assessed.
*These analytes were not listed in the original manufacturer specifications, but were requested to be included "as found".
Results and Discussion
The first survey report in the Body Fluids program was issued in May 2018. The BFWP elected to empirically widen the Analytical Performance Specifications (APS's) by at least twice those of the equivalent analytes in serum-based RCPAQAP Programs, namely General Chemistry, Tumour Markers, and Blood Gases. With further assessment of participant performance, the BFWP may choose to revise the APS's for some analytes.
The returned results for the surveyed analytes typically fell within the APS. Similar patterns and performance between several analytes in the Body Fluids and other RCPAQAP programs were evident; however, there were some analytes/methods where differences were noted.
Creatinine
Method differences were observed between enzymatic and Jaffe (alkaline picrate) methods for creatinine measurement, with participants using Jaffe methods generally returning lower concentrations of creatinine compared to those using enzymatic methods. As shown in Figure 1 , this pattern is similar to the General Chemistry program for samples at equivalent creatinine concentrations. The median difference between the two method types (median of Jaffe creatinine participants subtracted from the median of enzymatic creatinine participants) in the General Chemistry program is 8 mmol/L; however, the median difference between the same groups in the Body Fluids program was greater at 35 mmol/L. The sample with lower protein concentration (median 16 mmol/L) also had fewer returned results for creatinine, which may be due to these methods producing negative values in this setting.
The correction factor used in rate-blanked compensated Jaffe methods to allow for non-creatinine chromogens may explain the lower relative values in the Body Fluids matrix, compared to enzymatic methods. The effect of protein may be particularly important as this is often at a lower concentration in the body fluid samples. However, these differences are not clinically significant for body fluid analysis at these concentrations, as creatinine is mainly used to assess urine leakage post-surgery/trauma. The Body Fluids program includes some methods not used in the Blood Gases program, e.g. pH strips and certain pH meter brands; however, most laboratories (40 out of 43) quoted a blood gas instrument as their measuring device. Because the overall spread of results was so large, it was not possible to determine if there were any significant instrument/method-specific differences. The stability of the material may have been a factor, however further investigation is warranted, as body fluid pH is used to guide clinical decisions in some situations 1 .
Conclusions
Method differences were not immediately evident for most analytes in the Body Fluids program, except in the cases of creatinine and lactate. However, more may be revealed as more survey results are received with different analyte compositions. Further tightening of some APS's may highlight method differences in the future. Finally, it is important that the variable performance of pH is reviewed on an ongoing basis.
While recognising that a Body Fluids EQA program will not be able to simulate all scenarios in a laboratory setting, the initial results indicate that it should be a useful tool to assist laboratories in validating their methods for analysing various body fluids and ensuring ongoing acceptable performance. It is encouraging that most laboratories and platforms show concordance in analyte recoveries across the program. 
